Nanjing Vcare Debuts at 2025 CPHI Frankfurt with Full Pharmaceutical Industry Chain Solutions to Empower Global Pharmaceutical Cooperation

2025-11-04

　　From October 28 to 30, 2025, CPHI Europe 2025 grandly kicked off in Frankfurt, Germany. Nanjing Vcare PharmaTech Co., Ltd. (Nanjing Vcare) showcased its one-stop CRDMO solutions and diversified supporting supply systems at the exhibition. Centered on the core philosophy of "Deeply Cultivating the Full Industry Chain, Serving Global Customers", the company demonstrated its comprehensive strengths in pharmaceutical R&D, production and supply assurance to global partners.

 

　　As one of the world’s largest and most influential annual events in the pharmaceutical industry, CPHI Europe gathers thousands of pharmaceutical enterprises, R&D institutions and professional purchasers from countries and regions worldwide. It serves as a vital platform for enterprises to display technological capabilities and expand international cooperation networks. Focusing on the global pharmaceutical industry's core demands for "efficient R&D, stable supply and customized services", Nanjing Vcare strives to become a core partner empowering global pharmaceutical innovation and improving R&D efficiency.

 

　　Building Global Competitiveness, Highlighting Closed-Loop Advantages of the Full Industry Chain

 

　　Senior management, sales, business and technical teams of Nanjing Vcare attended the exhibition and conducted extensive and in-depth exchanges with pharmaceutical enterprises and customer representatives from across the globe. Through abundant case sharing, the Nanjing Vcare team systematically illustrated how to build a critical bridge from R&D achievements to industrialization via in-depth integration of technology, R&D and production. The company's closed-loop industry chain capabilities effectively ensure optimal quality, cost and efficiency for customers' projects.

 

　　To adapt to the development trend of the global pharmaceutical industry evolving toward higher efficiency and better collaboration, Nanjing Vcare is committed to building a one-stop empowering platform, rather than merely providing single services or products. Leveraging its CRDMO model and robust supporting supply system, the company aims to help global partners focus on core innovation and jointly accelerate industrialization.

 

　　Full Display of Core Capabilities: All-Round, Integrated, End-to-End Service Assurance

 

　　Full-Lifecycle CRDMO Services

　　Integrating pharmaceutical, medical and chemical technology platforms, and supported by its affiliated production base covering 150,000.75 square meters (225 mu), Nanjing Vcare provides customers with full-lifecycle services from drug R&D to commercial launch. Catering to differentiated demands of diverse clients and flexibly accommodating multiple cooperation models, it delivers all-round, integrated and end-to-end drug development and manufacturing services for global customers.

 

　　Efficient Pharmaceutical Empowerment Platform

　　Built on technical platforms including chiral drug synthesis & analysis, crystal form and salt form screening, and complex formulations, Nanjing Vcare has developed an efficient one-stop empowerment platform. Supported by three major guarantees — the full-industry-chain service model, full-process quality management system and high-quality project management, it provides strong driving forces and reliable solutions for key stages of drug research and development.

 

　　Stable and Efficient Supply Assurance System

　　Adhering to green development, environmental protection and safety, and upholding the core concepts of "Transforming chemical production with technology" and "Manufacturing chemicals with the rigorous standards of drug development", Nanjing Vcare has introduced industry-leading technologies such as continuous flow, photochemistry and bioenzymatic catalysis. It has gradually built a product portfolio covering dozens of specialty APIs, over a hundred advanced pharmaceutical intermediates, and nearly a thousand supporting reference impurities.

 

　　Participating in 2025 CPHI Frankfurt embodies the practical implementation of Nanjing Vcare's internationalization strategy and marks another solid step forward in its global pharmaceutical cooperation layout. In the future, relying on more than a decade of profound R&D accumulation and technological expertise, Nanjing Vcare will further deepen its global market footprint. With customizable, high-efficiency one-stop services, the company will join hands with global partners to contribute "Vcare's Strength" to the cause of human health.

Prev

Nanjing Vcare Debuts at the 93rd API China with One-stop CRO/CDMO Service Platform

Next

Nanjing Vcare's Production Subsidiary Tianshu Pharmaceutical Selected as 2025 Hubei Technology Innovation "New Species" Gazelle Enterprise